Literature DB >> 24434293

Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging.

Thomas Ebenhan1, Jan Rijn Zeevaart, Jacobus D Venter, Thavendran Govender, Gert H Kruger, Neil V Jarvis, Mike M Sathekge.   

Abstract

UNLABELLED: Antimicrobial peptides such as ubiquicidin (UBI) are believed to differentiate between mammalian and bacterial or fungal cells. (99m)Tc-UBI29-41 was previously tested for detecting infection in humans using SPECT. For the present study, the UBI fragment UBI29-41 (TGRAKRRMQYNRR) was conjugated to 1,4,7-triazacyclononane-triacetic acid (NOTA), radiolabeled with (68)Ga, and investigated in a rabbit infection model.
METHODS: (68)Ga was obtained from a 1.85-GBq (68)Ge/(68)Ga generator. New Zealand White rabbits were anesthetized with ketamine/medetomidine before tracer administration and placed in a clinical PET/CT scanner. (68)Ga-1,4,7-triazacyclononane-1,4,7-triacetic-acid-ubiquicidin29-41 ((68)Ga-NOTA-UBI29-41) was formulated in saline solution, and 101 ± 41 MBq were administered intravenously. The tracer distribution was studied by PET/CT imaging in animals (a) that were healthy, (b) bearing muscular Staphylococcus aureus infections and turpentine oil-induced muscular inflammations, and (c) bearing ovalbumin-induced lung inflammations. Static PET/CT imaging was performed at different time intervals up to 120 min after injection. For calculation of target-to-nontarget ratios, standardized uptake values were normalized against healthy thigh muscle, representing nontargeted tissue.
RESULTS: PET/CT images of healthy animals showed predominant distribution in the kidneys, liver, and bladder; heart and spleen showed moderate, declining uptake, only. The biologic half-life in blood was 29 min. Urinary accumulation of (68)Ga-NOTA-UBI29-41 peaked at 3.8 ± 0.91 percentage injected dose per gram (%ID) at 120 min, and 88 ± 5.2 %ID was recovered in total urine. (68)Ga-NOTA-UBI29-41 imaging in (b) selectively visualized the muscular infection site and was differentiated from sterile inflammatory processes. Standardized uptake value ratios for muscles (infected/inflamed) were 2.9 ± 0.93, 2.9 ± 0.50, 3.5 ± 0.86, and 3.8 ± 0.90 at 5, 30, 60, and 90 min after injection, respectively. Rabbit lungs with asthma showed insignificant uptake.
CONCLUSION: (68)Ga-NOTA-UBI29-41 was strongly localized in bacteria-infected areas and minimally detected in a sterile inflammation area in rabbit muscles. The findings propose this compound to be an excellent first-line PET/CT tracer to allow the distinguishing of infection from inflammation.

Entities:  

Keywords:  68Ga labeling; PET/CT Imaging; UBI29-41; infection; ubiquicidin

Mesh:

Substances:

Year:  2014        PMID: 24434293     DOI: 10.2967/jnumed.113.128397

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  A Systematic Approach for Developing Bacteria-Specific Imaging Tracers.

Authors:  Alvaro A Ordonez; Edward A Weinstein; Lauren E Bambarger; Vikram Saini; Yong S Chang; Vincent P DeMarco; Mariah H Klunk; Michael E Urbanowski; Kimberly L Moulton; Allison M Murawski; Supriya Pokkali; Alvin S Kalinda; Sanjay K Jain
Journal:  J Nucl Med       Date:  2016-09-15       Impact factor: 10.057

2.  Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.

Authors:  Jyotsna Bhatt; Archana Mukherjee; Aruna Korde; Mukesh Kumar; Haladhar Dev Sarma; Ashutosh Dash
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

Review 3.  Role of nuclear medicine in neuroHIV: PET, SPECT, and beyond.

Authors:  Mike Sathekge; Alicia McFarren; Ekaterina Dadachova
Journal:  Nucl Med Commun       Date:  2014-08       Impact factor: 1.690

Review 4.  Molecular imaging of bacterial infections: Overcoming the barriers to clinical translation.

Authors:  Alvaro A Ordonez; Mark A Sellmyer; Gayatri Gowrishankar; Camilo A Ruiz-Bedoya; Elizabeth W Tucker; Christopher J Palestro; Dima A Hammoud; Sanjay K Jain
Journal:  Sci Transl Med       Date:  2019-09-04       Impact factor: 17.956

5.  Specific Imaging of Bacterial Infection Using 6″-18F-Fluoromaltotriose: A Second-Generation PET Tracer Targeting the Maltodextrin Transporter in Bacteria.

Authors:  Gayatri Gowrishankar; Jonathan Hardy; Mirwais Wardak; Mohammad Namavari; Robert E Reeves; Evgenios Neofytou; Ananth Srinivasan; Joseph C Wu; Christopher H Contag; Sanjiv Sam Gambhir
Journal:  J Nucl Med       Date:  2017-05-10       Impact factor: 10.057

Review 6.  The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.

Authors:  Alfred O Ankrah; Andor W J M Glaudemans; Hans C Klein; Rudi A J O Dierckx; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2016-05-25

Review 7.  Advanced imaging tools for childhood tuberculosis: potential applications and research needs.

Authors:  Sanjay K Jain; Savvas Andronikou; Pierre Goussard; Sameer Antani; David Gomez-Pastrana; Christophe Delacourt; Jeffrey R Starke; Alvaro A Ordonez; Patrick Jean-Philippe; Renee S Browning; Carlos M Perez-Velez
Journal:  Lancet Infect Dis       Date:  2020-06-23       Impact factor: 25.071

Review 8.  Pathogen-Specific Bacterial Imaging in Nuclear Medicine.

Authors:  Alvaro A Ordonez; Sanjay K Jain
Journal:  Semin Nucl Med       Date:  2017-12-14       Impact factor: 4.446

9.  Synthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agent.

Authors:  Botshelo B Mokaleng; Thomas Ebenhan; Suhas Ramesh; Thavendran Govender; Hendrik G Kruger; Raveen Parboosing; Puja P Hazari; Anil K Mishra; Biljana Marjanovic-Painter; Jan R Zeevaart; Mike M Sathekge
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

Review 10.  Antimicrobial peptides: their role as infection-selective tracers for molecular imaging.

Authors:  Thomas Ebenhan; Olivier Gheysens; Hendrick Gert Kruger; Jan Rijn Zeevaart; Mike Machaba Sathekge
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.